DBV Technologies: Mixed General Assembly of June 21, 2016 Procedures for obtaining preparatory documents for the Assembly
(Thomson Reuters ONE) -
Regulated Information
Montrouge, France, May 30, 2016
Mixed General Assembly of June 21, 2016
Procedures for obtaining preparatory documents for the Assembly
DBV Technologies, (Euronext: DBV - ISIN: FR0010417345 - NASDAQ: DBVT), a
clinical-stage specialty biopharmaceutical company, announces that it will hold
its Mixed General Assembly on June 21, 2016 at 8:30 a.m. at the company
headquarters: 177-181 Avenue Pierre Brossolette - 92120 Montrouge (France).
The notice containing the agenda and draft resolutions was published in the BALO
of 16 May 2016. The notice stating the time and place of the meeting will be
published in the BALO of June 6, 2016 and in a legal gazette on June 6, 2016.
The preparatory documents for the Assembly listed in Article R. 225-73-1 of the
French Commercial Code are posted on the company's website in the Investor
Relations section: http://www.dbv-technologies.com/en/investor-
relations/general-meeting.
The preparatory documents for the Assembly will also be made available to
shareholders as of the convening of the meeting. Thus, in accordance with
applicable regulatory provisions:
* All registered shareholders may, until five days (included) before the
Assembly, request that the Company send them these documents, at their
express request by electronic means. For holders of bearer shares, the
exercise of this right is subject to the provision of a certificate of
participation in the bearer share accounts held by the authorized
intermediary;
* Any shareholder may consult the documents referred to in Articles L.
225-115 and R. 225-83 of the French Commercial Code at the company
headquarters.
About DBV Technologies
DBV Technologies developed Viaskin®, a proprietary technology platform with
broad potential applications in immunotherapy. Viaskin is based on epicutaneous
immunotherapy, or EPIT®, DBV's method of delivering biologically active
compounds to the immune system through intact skin. With this new class of self-
administered and non-invasive product candidates, the company is dedicated to
safely transforming the care of food allergic patients, for whom there are no
approved treatments. DBV's food allergies programs include ongoing clinical
trials of Viaskin Peanut and Viaskin Milk, and preclinical development of
Viaskin Egg. DBV is also pursuing a human proof concept clinical study of
Viaskin Milk for the treatment of Eosinophilic Esophagitis, and exploring
potential applications of its platform in vaccines and other immune diseases.
DBV Technologies has global headquarters in Montrouge, France and New York, NY.
Company shares are traded on segment B of Euronext Paris (Ticker: DBV, ISIN
code: FR0010417345), part of the SBF120 index, and traded on the Nasdaq Global
Select Market in the form of American Depositary Shares (each representing one-
half of one ordinary share) (Ticker: DBVT). For more information on DBV
Technologies, please visit our website: www.dbv-technologies.com
DBV Technologies Contact
Susanna Mesa
Senior Vice President, Strategy
+1 212-271-0861
susanna.mesa(at)dbv-technologies.com
Media Contacts
Erinn White, Centron PR
+1 646-722-8822
ewhite(at)centronpr.com
Marion Janic, Rooney & Associates
+1 212-223-4017
mjanic(at)rooneyco.com
Media Contacts, Europe
Caroline Carmagnol, Alize RP - Relation Presse
+33 (0)6 64 18 99 59
caroline(at)alizerp.com
PDF Version:
http://hugin.info/156437/R/2016337/747789.pdf
This announcement is distributed by GlobeNewswire on behalf of
GlobeNewswire clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: DBV Technologies via GlobeNewswire
[HUG#2016337]
Unternehmensinformation / Kurzprofil:
Datum: 30.05.2016 - 22:31 Uhr
Sprache: Deutsch
News-ID 474414
Anzahl Zeichen: 4701
contact information:
Town:
Bagneux
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 236 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"DBV Technologies: Mixed General Assembly of June 21, 2016 Procedures for obtaining preparatory documents for the Assembly"
steht unter der journalistisch-redaktionellen Verantwortung von
DBV Technologies (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
